ChemoCentryx Inc. sold the Chinese commercialization rights to its kidney disease medicines CCX140 and avacopan to Vifor Pharma AG for an up-front cash payment of $21.5 million.
Switzerland's Vifor will also pay a royalty on the sales of the drugs, once they are commercialized.
Mountain View, Calif.-based ChemoCentryx continues to retain the U.S. commercialization rights to the medicines.
The companies previously agreed to partner on the development of the drugs.
